Month: February 2022

Feb 10 2022

Uncategorized

Schizophrenia Drugs Market is Boosting the Healthcare Industry Worldwide

by Clinical Editor

No Comments

A report by Transparency Market Research states that global schizophrenia drugs market is projected to witness a substantial growth in the duration of 2019 to 2027. According to the expert...

Feb 10 2022

Uncategorized

Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia

by Clinical Editor

No Comments

Alkermes plc’s (NASDAQ: ALKS) ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan) met its prespecified primary endpoint on body weight in young schizophrenia adult patients in the …

Feb 10 2022

Uncategorized

Alkermes says its schizophrenia trial met main goal with less weight gain in patients

by Clinical Editor

No Comments

Alkermes (NASDAQ:ALKS) is trading ~6% higher on Monday after the company announced topline results from its ENLIGHTEN-Early trial suggesting the Phase 3 study for the schizophrenia therapy LYBALVI …

Feb 10 2022

Uncategorized

Injectables for Schizophrenia Reduce Hospitalizations Better Than Oral Medications, Study Shows

by Clinical Editor

No Comments

Long-acting injectables for schizophrenia reduce the risk of hospitalization better than oral medications, according to new research.

Feb 10 2022

Uncategorized

What to Know About Hallucinations and Schizophrenia

by Clinical Editor

No Comments

Even if you don’t know much about schizophrenia, you might know this mental health condition commonly involves hallucinations. A hallucination happens when you receive sensory information that …

Feb 09 2022

Uncategorized

Schizophrenia: What It Is and Is Not – Psychology Today

by Clinical Editor

No Comments

Schizophrenia: What It Is and Is Not  Psychology Today

Feb 09 2022

Uncategorized

Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia

by Clinical Editor

No Comments

Alkermes plc’s (NASDAQ: ALKS) ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan) met its prespecified primary endpoint on body weight in young schizophrenia adult patients in the …

Feb 09 2022

Uncategorized

Alkermes says its schizophrenia trial met main goal with less weight gain in patients

by Clinical Editor

No Comments

Alkermes (NASDAQ:ALKS) is trading ~6% higher on Monday after the company announced topline results from its ENLIGHTEN-Early trial suggesting the Phase 3 study for the schizophrenia therapy LYBALVI …

Feb 09 2022

Uncategorized

What to Know About Hallucinations and Schizophrenia

by Clinical Editor

No Comments

Even if you don’t know much about schizophrenia, you might know this mental health condition commonly involves hallucinations. A hallucination happens when you receive sensory information that …

Feb 09 2022

Uncategorized

Injectables for Schizophrenia Reduce Hospitalizations Better Than Oral Medications, Study Shows

by Clinical Editor

No Comments

Long-acting injectables for schizophrenia reduce the risk of hospitalization better than oral medications, according to new research.